The eternal orphan

August 28, 2008

Implemented in 1983, the basic intent of the US Orphan Drug Act (ODA) was to stimulate research, development, and approval of products that treat rare diseases. “In the US, these diseases are defined as those which affect less than 2,00,000 patients or those for which cost of development is unlikely to be covered through commercialisation. ‘Orphan drugs’ are thus used for rare diseases for which there is an unmet medical need,” says Dr Chandrashekhar Potkar, Director-Medical and Regulatory Affairs, Pfizer. Examples of these diseases include severe combined immunodeficiency syndrome, cystic fibrosis, hairy cell leukaemia etc. Malaria and tuberculosis also are orphan indications in the US. The concept of orphan drug in the US, apart from covering pharmaceutical or biological products, also covers medical devices and dietary or diet products.

“There is limited commercial opportunity for such drugs. However, research based pharma companies are able to apply their R&D expertise in partnership with government and other medical institutes for orphan indications with unmet medical needs,” Potkar adds. Government provides incentives for sponsors undertaking research on orphan indications. These incentives can take form of tax credits for clinical research expenditure, grants in aid for clinical research, design assistance for investigating orphan indications (eg. open protocols for enrolling patients) and seven year market exclusivity. But the definition of orphan drugs and diseases and the incentives attached to them may vary in different countries depending on the prevalence of diseases there and the respective population strengths.

It is the enforcement of this very Act that encouraged other countries, including European Union (EU), Australia, Japan and Singapore to follow suit. So what is stopping India from adopting a legislation similar to the Act? Potkar says that this may be due to the fact that our current legislation is focused on strengthening R&D in India.

Dr Syamala Ariyanchira, author of BCC Research‘s Global Markets for Orphan Drugs report, opines, “Considering that there are next to none pharma companies in India manufacturing or researching orphan drugs to my knowledge, there will be no incentives for them. However, in 2001, a group of pharmacologists at an Indian Drug Manufacturing Association (IDMA) conference had appealed to the Indian Government to form something akin to the Orphan Drug Act. But I have not heard of any kind of development in this context since then.”¹

¹Aashruti Kak; Express Pharma

read more | digg story

Bookmark and Share

Advertisements

$300m shot in the arm for Merck’s vaccines plant

July 24, 2008

US drug giant Merck & Co hopes that an additional $300m investment in its vaccine manufacturing plant in Durham, North Carolina will cement its position at the forefront of the global vaccines market.¹

¹Gareth McDonald; In-PharmaTechnologist.com

read more | digg story

Bookmark and Share


Ultrasonics Slated for a High Growth

July 23, 2008

According to a new technical market research report, “Ultrasonics: Global Markets and Technologies” (MFG013C) from BCC Research, the global market for ultrasonic technology was worth $10.8 billion in 2007. This is expected to increase to $12.4 billion in 2008 and reach $18.8 billion by 2013, a compound annual growth rate (CAGR) of 8.7%.¹

¹BCC Research; Controlled Environments Magazine

read more | digg story

Bookmark and Share


DNA Vaccine Development Making Strides

July 9, 2008

While traditional antigen-based products will continue to dominate the sector, the benefits offered by DNA vaccines in terms of minimized side effect profile make any successful technology an attractive proposition.¹

¹Gareth Macdonald; In-pharmatechnologist.com

read more | digg story

Bookmark and Share


Patients and doctors finding benefits in probiotics

July 9, 2008

PEORIA — Probiotics have long resided in the human gut. Only recently has the word moved to the tip of the tongue of many central Illinoisans. “People read about it and are interested,” said Dr. Antoine Dawalibi, who practices family medicine at Methodist Medical Group at Peartree. ¹

¹Ori, Ryan Peoria Illinois Journal

read more | digg story

Bookmark and Share


Pondering Probiotics

June 12, 2008

What if, rather than conferring a benefit to the digestive tract, probiotics worked by slowing the pace of bacterial die-off in organs near the gut, or even in other areas of the gut itself?¹

¹Amy Proal; Bacteriality–Understanding Chronic Disease

read more | digg story

Bookmark and Share


Industry Insider: A click closer to Rx information

June 12, 2008

More consumers are going online to look up information about medications, and they’re more likely to click on prescription drug ads they find there, a new survey about direct-to-consumer ads in the pharmaceutical industry found.¹

¹Jeff May and Robert Cohen/The Star-Ledger

read more | digg story

Bookmark and Share